Exchange: NASDAQ·Updated 07:51 PM EST

CGTX News

News
all
press releases
What Makes Cognition Therapeutics (CGTX) a New Buy Stock
Cognition Therapeutics (CGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
What Makes Cognition Therapeutics (CGTX) a New Buy Stock
Cognition Therapeutics (CGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
More News
Cognition Therapeutics (CGTX) delivered earnings and revenue surprises of +33.33% and -120.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
The company reported that the U.S. Food and Drug Administration aligned with the company on several key aspects of the Phase 3 study, which is expected to begin in mid-2027.
Stocktwits
Cognition Therapeutics (NASDAQ:CGTX) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-cognition-therapeutics-inc-stock...
MarketBeat
Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) has received a consensus rating of "Moderate Buy" from the four analysts that are covering the firm, MarketBeat reports. One research...
MarketBeat
Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) CEO Lisa Ricciardi bought 9,175 shares of the company's stock in a transaction dated Thursday, April 16th. The shares were acquired at an...
MarketBeat
Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) CFO John Brendan Doyle bought 10,000 shares of the stock in a transaction that occurred on Thursday, April 16th. The shares were bought at an average cost of $1.13 per share, with a total value of $11,300.00. Following the completion of...
MarketBeat
Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) CEO Lisa Ricciardi acquired 9,175 shares of the business's stock in a transaction that occurred on Thursday, April 16th. The shares were purchased at an average price of $1.10 per share, with a total value of $10,092.50. Following the...
MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) executives told investors at the Needham conference that the company is preparing to advance its once-daily oral candidate zervimesine into late-stage...
MarketBeat
Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Cognition Therapeutics in a research report issued on Friday...
MarketBeat

Advertisement|Remove ads.